In this rationale, the research conducted by Takwi et al. established that the miR-137 promoter hypermethylation, along with its negative regulation by CAR, partially accounts for the mitigated transcriptional level of miR-137 and the elevated levels of CAR and P-gp in doxorubicin-resistant neuroblastoma cells. The gene discussed is NR1I3; the disease is neuroblastoma.